Advances in Pancreatic Cancer: Expert Insights to Guide Clinical Practice

In this expert commentary, contemporary therapy for patients with resectable and advanced pancreatic cancer are discussed, with a focus on neoadjuvant and adjuvant therapy strategies and targeted therapies for cancers with actionable mutations.

Dan Laheru, MD Released: February 5, 2021

Download this concise slideset for expert perspectives on first-line systemic therapy considerations for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director Released: February 17, 2021

Download this concise slideset for expert perspectives on second-line systemic therapy considerations for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director Released: February 19, 2021

Download this concise slideset for expert insights into the use of PARP inhibitors as maintenance therapy for patients with advanced pancreatic cancer and specific molecular alterations.

Paul E. Oberstein, MD
Program Director Released: March 5, 2021

Download this concise slideset for expert insights into the current optimal use of neoadjuvant and adjuvant therapy strategies for patients with resectable or borderline resectable pancreatic cancer.

Paul E. Oberstein, MD
Program Director Released: March 1, 2021

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with pancreatic cancer with those of 5 renowned experts.

Andrew H. Ko, MD
Program Director Elena Gabriela Chiorean, MD Dan Laheru, MD Paul E. Oberstein, MD Michael J. Pishvaian, MD, PhD Released: September 13, 2021

This brief activity provides expert insights into the selection of first-line systemic therapy for patients with advanced pancreatic cancer based on best available evidence.

Andrew H. Ko, MD
Program Director Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 17, 2021 Expired: No longer available for credit

This short activity provides expert insights into selection of second-line systemic therapy for patients with advanced pancreatic cancer.

Andrew H. Ko, MD
Program Director Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 19, 2021 Expired: No longer available for credit

This brief virtual presentation provides expert insights into the use of PARP inhibitors as maintenance therapy for patients with advanced pancreatic cancer and specific molecular alterations.

Paul E. Oberstein, MD
Program Director Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 5, 2021 Expired: No longer available for credit

This brief virtual presentation provides expert insights into the current optimal use of neoadjuvant and adjuvant therapy strategies for patients with resectable or borderline resectable pancreatic cancer.

Paul E. Oberstein, MD
Program Director Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 1, 2021 Expired: No longer available for credit